Search

Displaying results 1871 - 1880 of 10000 in total
  1. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. … [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.

  2. Drug

    Pidolic acid

    go.drugbank.com/drugs/DB03088
    ApprovedInvestigational

    Pidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin [L2729]. … in various chemical pathways [A32991, L2729].

  3. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone) … for the treatment of postpartum depression (PPD) in adult females [F4066].

  4. Drug

    Minoxidil

    go.drugbank.com/drugs/DB00350
    ApprovedInvestigational

    A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.

    Categories: Arteriolar Smooth Muscle, Agents Acting OnProducts: Hair Growth Serum Roll-ON, TRIATOP®ESPUMA TÓPICA EN AEROSOL
  5. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at

  6. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.

    Categories: Drugs Used in Diabetes
  7. Drug

    Lenacapavir

    go.drugbank.com/drugs/DB15673
    ApprovedInvestigational

    [A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy _in vitro_, little to no cross-resistance with existing antiretroviral … HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens

    Synonyms: N-((1S)-1-(3-(4-CHLORO-3-(METHANESULFONAMIDO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-(METHANESULFONYL)-3-METHYLBUT-1-YN-1-YL)PYRIDIN-2-YL)-2-(3,5- DIFLUOROPHENYL)ETHYL)-2-((3BS,4AR)-5,5-DIFLUORO, 1H-CYCLOPROPA(3,4)CYCLOPENTA(1,2-C)PYRAZOLE, N-((1S)-1-(3-(4-CHLORO-3-((METHYLSULFONYL)AMINO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-METHYL-3-(METHYLSULFONYL)-1-BUTYN-1-YL)-2-PYRIDINYL)-2-(3,5-
  8. Drug

    Chenodeoxycholic acid

    go.drugbank.com/drugs/DB06777
    ApprovedInvestigational

    Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. … It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.

  9. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    The defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. … Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers.

  10. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl. … The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost].

    Synonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinate